ANTITHROMBOTIC THERAPY IN 2017: Advances in atherosclerosis, atrial fibrillation, and valvular disease

    loading  Checking for direct PDF access through Ovid


In 2017, several high-impact studies in thrombosis were published. Refinements were made in the optimal therapy for patients with stable atherosclerosis or with atrial fibrillation undergoing percutaneous coronary intervention. Risk scores to determine duration of antiplatelet therapy were developed. The potential risk of subclinical valve leaflet thrombosis was identified.

Related Topics

    loading  Loading Related Articles